Form 4: Travere Therapeutics Executive Sells Shares to Cover Tax Obligations

A Travere Therapeutics executive sold 925 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Sandra Calvin, SVP and Chief Accounting Officer at Travere Therapeutics, sold 925 shares of common stock on January 22, 2025.
• The sale was executed at a price of $18.9408 per share.
• This transaction was not a discretionary trade but rather a 'sell to cover' transaction mandated by the company to cover tax withholding obligations related to vested restricted stock units.
• Following the transaction, Ms. Calvin directly owns 54,002 shares of Travere Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• Many publicly traded companies use 'sell to cover' transactions to manage tax obligations for employees receiving equity compensation.
• The sale of 925 shares is a relatively small transaction compared to the total shares outstanding for Travere Therapeutics.
• The price of $18.9408 is within the normal trading range for the company's stock.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale related to tax obligations.

Key Dates

Keywords

Travere Therapeutics, insider trading, stock sale, tax obligations, equity compensation, Form 4, Sandra Calvin